Latanoprost versus timolol gel to prevent ocular hypertension after phacoemulsification and intraocular lens implantation.
OBJECTIVE
To evaluate the efficacy of latanoprost and timolol gel in preventing ocular hypertension in the early period after phacoemulsification and posterior chamber intraocular lens (PC IOL) implantation.


METHODS
Department of Ophthalmology and Visual Sciences, Prince of Wales Hospital, Hong Kong, China.


METHODS
This prospective randomized double-masked clinical trial comprised patients with uncomplicated cataract having phacoemulsification with PC IOL implantation. They were randomly assigned to 1 of 3 groups: postoperative application of timolol 0.5% gel-forming solution (Timoptol-XE(R)) (Group 1), latanoprost 0.005% (Group 2), and control (Group 3). Intraocular pressure (IOP) was measured 2, 4, and 24 hours postoperatively. The anterior chamber was examined for the levels of cells and flare using slitlamp biomicroscopy.


RESULTS
Group 1 had a significantly greater reduction in mean IOP 2, 4, and 24 hours after phacoemulsification and PC IOL implantation than Group 3 (P <.05). There were no significant differences between Groups 2 and 3 at any interval (P. 05). No excessive postoperative anterior chamber inflammation was observed in any group.


CONCLUSIONS
A single dose of latanoprost given after phacoemulsification and PC IOL implantation did not produce a significant IOP-lowering effect when compared with a control group in the first 24 hours postoperatively. A single dose of timolol gel produced a significant postoperative IOP decrease as soon as 2 hours and up to 24 hours after surgery. Timolol gel and latanoprost are safe, but timolol is more effective than latanoprost in preventing postoperative ocular hypertension.
Lai
J S
JS
Department of Ophthalmology and Visual Sciences, the Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, People's Republic of China.
Chua
J K
JK
Leung
A T
AT
Lam
D S
DS
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D000368:Aged; D000867:Anterior Chamber / Q000473:pathology; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D002452:Cell Count; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D019654:Lens Implantation, Intraocular / Q000009:adverse effects*; D008297:Male; D009798:Ocular Hypertension / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D018918:Phacoemulsification / Q000009:adverse effects*; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage*; D013999:Timolol / Q000008:administration & dosage*; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D005782:Gels; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; D013999:Timolol